Trial reportThe journal of headache and pain2026
Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study.
Trial report in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03867201 (A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundErenumab is a fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor. Several double-blind studies have demonstrated the clinical benefits of erenumab in migraine prevention. However, long-term studies on safety and effectiveness of erenumab are lacking in Asian population.
objectivesTo evaluate the long-term safety and continued clinical benefit of erenumab 70 mg in adult patients with chronic migraine (CM) in China and other Asian countries.
methodsThis was an open-label extension of the Phase 3 DRAGON study. Upon completion of the 12-week, double-blind treatment phase (DBTP) of the DRAGON study, randomized patients who met the inclusion criteria and provided consent transitioned into an open-label treatment phase (OLTP) lasting until erenumab approval in the patient's country. During OLTP, patients received once-monthly subcutaneous injection of erenumab 70 mg, irrespective of their initial treatment allocation in DBTP. Safety was assessed by collecting all adverse events (AEs) and serious AEs (SAEs) including their severity and relationship to study treatment. Effectiveness outcomes included clinical global impression (CGI) [severity (CGI-S), improvement (CGI-I), and efficacy index (CGI-E)].
resultsOf the 557 randomized patients (DBTP), 456 from 50 centers participated and 226 (49.6%) completed OLTP. The median duration of exposure to erenumab was 79.9 weeks (interquartile range: 39.9-130.5). Overall, 328 (71.9%) patients reported at least one AE during OLTP. AEs suspected to be related to treatment were reported in 69 (15.1%) patients, with constipation (34 [7.5%]) being the most frequent treatment-related AE. There were 13 (2.9%) patients who discontinued the study drug due to AEs. Breast cancer was reported as an AE leading to discontinuation in 2 (0.4%) patients (not treatment related). SAEs were reported in 45 (9.9%) patients during OLTP, of which only 3 (0.7%) were treatment-related (all resolved). Continued clinical benefit with erenumab 70 mg as assessed by CGI E/I/S scores were observed for participating patients during OLTP.
conclusionErenumab 70 mg showed a consistent and well-tolerated safety profile observed over a longer treatment duration along with sustained clinical benefit. No new safety signals were observed versus DBTP and prior global phase 3 studies.
trial registrationClinicalTrials.gov ID (DRAGON) NCT03867201 (registration date 2019-03-07).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.